Table 1.

Characteristics of returned travellers with systemic endemic mycoses reported to GeoSentinel, January 1997 to December 2017^a

Characteristic	Histoplasmosis (n = 51)	Coccidioidomycosis (n = 14)	Blastomycosis (n = 3)
Median age, years (range)	30 (8–85)b	62 (22–78)	48 (31–56)
Sex, n (%)
• Female	20 (39%)	4 (29%)	1 (33%)
Pretravel consultation, n (%)
• Yes	9 (18%)	2 (14%)	2 (67%)
• No	14 (27%)	6 (43%)	1 (33%)
• Unknown	28 (55%)	6 (43%)	0
Reasons for travel, n (%)
• Business	2 (4%)	3 (21%)	0
• Education/student	17 (33%)	0	0
• Military	0	1 (7%)	0
• Missionary/volunteer/researcher/aid work	3 (6%)	0	0
• Tourism	25 (49%)	10 (72%)	2 (67%)
• Visiting friends and relatives	4 (8%)	0	1 (33%)
Region of exposure
• Caribbean	2 (4%)	0	0
• Central America	34 (66%)	1 (7%)	1 (33%)
• North America	0	13 (93%)	0
• North East Asia	0	0	1 (33%)
• South America	11 (22%)	0	0
• Southeast Asia	1 (2%)	0	1 (33%)
• Sub-Saharan Africa	3 (6%)	0	0
Median duration of travel, days (range)c,d	12 (5–154)	43 (23–821)	8
Median days between return and presenting to a GeoSentinel site (range)e	16 (1–137)	55 (17–273)	5
Hospitalized	24 (47%)	4 (29%)	0
Co-morbid conditions
• None known to exist	46 (90%)	12 (86%)	3 (100%)
• HIV/AIDS	3 (6%)	0	0
• Others	2 (4%)f	2 (14%)g	0

^aData on the one traveller with talaromycosis is not presented in the table.

^bData for two travellers missing.

^cAmong those who travelled to one destination country only (n = 44).

^dData for 14 travellers missing [histoplasmosis (n = 6), coccidioidomycosis (n = 5), blastomycosis (n = 2)].

^eData for 15 travellers missing [histoplasmosis (n = 7), coccidioidomycosis (n = 5), blastomycosis (n = 2)].

^fImmunosuppressing/immunomodulating agents [currently or within 3 months of clinic visit (n = 1)], «other» immunocompromising condition (n = 1).

^gImmunosuppressing/immunomodulating agents [currently or within 3 months of clinic visit (n = 1)], insulin-dependent diabetes mellitus (n = 1)